Home Inherited Disease and Carrier Screening Tuberous Sclerosis Genetic Test: TSC1, TSC2 Genes, Risk, and Results

Tuberous Sclerosis Genetic Test: TSC1, TSC2 Genes, Risk, and Results

By
Vita Library
-
3
Understand TSC1 and TSC2 genetic testing for tuberous sclerosis, including diagnostic results, VUS, negative tests, mosaicism, inheritance risk, and surveillance.

A tuberous sclerosis genetic test analyzes TSC1 and TSC2 for variants that disrupt regulation of cell growth. A pathogenic or likely pathogenic variant in either gene can establish a molecular diagnosis of tuberous sclerosis complex (TSC), even before the person has enough visible findings to meet clinical criteria. That makes the result unusually consequential: it can trigger brain, kidney, heart, lung, skin, eye, dental, and developmental surveillance across the lifespan. Testing also has limitations. Standard sequencing may miss exon-level deletions, complex rearrangements, deep splice variants, or low-level mosaicism. A negative blood test therefore does not exclude TSC when clinical features are convincing. Result interpretation must distinguish a constitutional variant present throughout the body from a mosaic variant present in only a proportion of cells, and a diagnostic pathogenic variant from a variant of uncertain significance. The gene name alone cannot predict the number of organs involved, seizure severity, intellectual outcome, or future tumor growth.

  • TSC is usually caused by one pathogenic variant in TSC1 or TSC2 and follows autosomal dominant inheritance.
  • A pathogenic or likely pathogenic result is molecularly diagnostic; a VUS is not.
  • Testing should include sequencing and deletion/duplication analysis of both genes.
  • Deep, high-coverage testing of blood or other tissues may be needed when mosaicism is suspected.
  • A confirmed result should lead to guideline-based multisystem evaluation and family-risk counseling.

Table of Contents

How TSC1 and TSC2 cause a multisystem disorder

TSC1 encodes hamartin and TSC2 encodes tuberin. Together with TBC1D7, these proteins form a complex that restrains the mechanistic target of rapamycin complex 1, or mTORC1. mTORC1 helps control cell growth, protein production, metabolism, and responses to nutrients. When one working copy of TSC1 or TSC2 is lost throughout the body and a second local event disables the remaining copy in a cell lineage, mTOR signaling can become overactive and contribute to hamartomas and other lesions.

That biology helps explain why TSC affects many organs but not in a uniform pattern. Features may include:

  • hypomelanotic macules, facial angiofibromas, shagreen patches, ungual fibromas, or other skin findings;
  • cortical tubers, radial migration lines, subependymal nodules, or subependymal giant cell astrocytoma (SEGA) in the brain;
  • seizures, developmental differences, autism, attention or mood symptoms, sleep problems, and other TSC-associated neuropsychiatric disorders (TAND);
  • renal angiomyolipomas, kidney cysts, hypertension, impaired kidney function, or less commonly renal malignancy;
  • cardiac rhabdomyomas or rhythm abnormalities, particularly in infancy and childhood;
  • pulmonary lymphangioleiomyomatosis (LAM), especially in adult women, and other lung findings;
  • retinal hamartomas, dental enamel pits, oral fibromas, and bone lesions.

The manifestations are age-dependent. A fetus may first be recognized because of cardiac rhabdomyomas. An infant may present with hypomelanotic macules or seizures. Kidney and lung complications may become more important in adulthood. An apparently healthy person with a familial variant may still develop features later, which is why molecular diagnosis can precede clinical diagnosis.

TSC is a tumor-predisposition and neurodevelopmental disorder, but most characteristic growths are benign. Their location, size, bleeding risk, effect on organ function, and response to mTOR inhibition determine clinical significance. Genetic testing identifies the underlying predisposition; it does not show whether a particular lesion is currently growing or requires treatment.

Clinical diagnosis versus molecular diagnosis

TSC can be diagnosed clinically or molecularly. The two routes complement rather than replace each other.

Under current international criteria, a definite clinical diagnosis is established by two major features or one major feature plus at least two minor features. One major feature or at least two minor features can support a possible diagnosis. The combination of LAM and renal angiomyolipomas alone has a special limitation and does not automatically establish definite TSC without additional features, because that combination can occur in sporadic LAM.

A molecular diagnosis is established by a heterozygous pathogenic or likely pathogenic variant in TSC1 or TSC2. The variant is considered sufficient because features accumulate with age and may be subtle. A young child or adult relative can therefore have a diagnostic result before imaging or examination reveals the usual pattern.

Genetic testing is commonly ordered when:

  • clinical findings meet or approach TSC criteria;
  • fetal or neonatal cardiac rhabdomyomas raise suspicion;
  • a person has unexplained cortical tubers, subependymal nodules, SEGA, multiple renal angiomyolipomas, or characteristic skin lesions;
  • a relative has a known TSC1 or TSC2 variant;
  • the phenotype overlaps another neurocutaneous, renal, epilepsy, or tumor-predisposition disorder;
  • reproductive or prenatal testing is being considered.

Clinical criteria remain decisive when testing is negative. A person with two major features does not lose the diagnosis because no variant is found in blood. Conversely, one isolated feature and a VUS do not equal TSC. The clinician must assess whether the variant classification and phenotype independently meet diagnostic standards.

A careful evaluation often includes a dermatologic examination with a Wood’s lamp, brain MRI, kidney imaging, blood pressure and renal function, cardiac studies when age-appropriate, eye and dental examinations, developmental and psychiatric screening, and lung assessment in relevant adults. The exact workup depends on age, sex, symptoms, and findings. Genetic testing should be coordinated with this evaluation rather than used as a shortcut around it.

What a complete TSC genetic test should cover

A first-line molecular test should usually evaluate both TSC1 and TSC2. Testing only one gene is rarely efficient unless a familial variant is already known.

Sequence analysis detects many substitutions, small insertions or deletions, nonsense changes, and splice-region variants. TSC1 pathogenic variants frequently truncate hamartin. TSC2 has a broader variant spectrum, including missense and splice findings that can be harder to classify.

Deletion and duplication analysis is also necessary. Ordinary sequence analysis may not detect loss or gain of one or more exons or an entire gene. TSC2 is particularly important because larger rearrangements occur, including deletions that extend into the adjacent PKD1 gene. This TSC2/PKD1 contiguous-gene deletion can cause TSC together with early, severe polycystic kidney disease and requires focused renal management.

A multigene panel can be useful when the diagnosis is uncertain. Depending on the presentation, it may include genes associated with focal cortical dysplasia, epilepsy, renal cysts or angiomyolipomas, neurocutaneous syndromes, or mTOR-pathway disorders. Panels can identify a better explanation but also increase the chance of uncertain or unrelated findings. A focused genetic panel should be chosen around the phenotype.

The laboratory report should disclose:

  • coding and splice regions assessed;
  • whether deletion/duplication analysis was performed;
  • sequencing depth and the lowest mosaic variant fraction validated;
  • ability to detect complex rearrangements;
  • whether intronic or RNA analysis is available;
  • specimen type;
  • transcript and genome reference used;
  • categories of variants reported.

Exome sequencing may detect many TSC1 and TSC2 coding variants but can have limited copy-number or low-level mosaic sensitivity. Genome sequencing can improve coverage of intronic and structural regions, but analysis pipelines still vary. A negative exome should not be assumed equivalent to a high-depth, mosaic-sensitive TSC study.

When a splice effect is suspected, RNA analysis can show whether the variant causes exon skipping or abnormal transcript processing. Functional studies may help resolve selected missense variants, but research assays are not automatically sufficient for clinical classification. Any result used for diagnosis or family testing should be confirmed and reported by a clinical laboratory.

How to interpret positive, VUS, and negative results

A TSC report is most useful when it states the gene, exact variant, classification, estimated allele fraction, method, and whether the finding explains the phenotype.

Pathogenic or likely pathogenic variant detected. A heterozygous result in TSC1 or TSC2 establishes a molecular diagnosis under current criteria. “Likely pathogenic” is considered actionable for clinical diagnosis, not a tentative VUS. The person should receive baseline and ongoing TSC surveillance even if few features are apparent.

Variant of uncertain significance detected. A VUS neither confirms nor rules out TSC. It may later be reclassified after additional families, population data, RNA studies, or functional evidence become available. Clinical management should be based on the person’s established findings and diagnostic criteria, not on uncertainty alone. Testing healthy relatives solely for a VUS is generally not predictive, although segregation studies may sometimes help the laboratory interpret it. See VUS result interpretation for the broader principles.

No pathogenic variant detected. A negative result does not exclude TSC. Standard testing can miss low-level mosaic variants, deep-intronic splice changes, structural variants, or regions with inadequate coverage. Some clinically diagnosed individuals remain without an identifiable molecular cause after conventional TSC1/TSC2 analysis. The strength of a negative result depends on whether sequencing, copy-number testing, and mosaic-sensitive analysis were all performed.

Benign or likely benign variant. These changes are not considered a cause of TSC and should not drive surveillance or reproductive testing. A report may list them only when they affect assay interpretation or are part of a haplotype.

Multiple findings. Two reported variants do not imply recessive inheritance. TSC is usually caused by one heterozygous pathogenic variant. The laboratory must determine whether an additional finding is benign, uncertain, mosaic, part of a complex rearrangement, or relevant to another condition.

Unexpected pathogenic result. TSC1 or TSC2 may be found on a broad epilepsy, kidney, tumor, exome, or genome test in someone not previously suspected of TSC. The result should be confirmed, the phenotype reviewed, and age-appropriate baseline evaluation arranged. Mild expression can make the diagnosis easy to miss, but an isolated database assertion should not substitute for clinical laboratory classification.

Variant nomenclature matters. Family testing and prenatal diagnosis require the exact cDNA and protein change or deletion coordinates, not a phrase such as “TSC gene positive.” Keep the complete report because classifications and assay capabilities can change.

Mosaicism and why blood testing can miss it

Mosaicism occurs when a TSC1 or TSC2 variant arises after fertilization, so only a subset of cells carries it. The timing and developmental lineage of the event determine which tissues are involved and what fraction of cells is affected. Mosaic TSC can be mild, segmental, or fully diagnostic, and severity cannot be inferred from the blood percentage alone.

A routine blood assay may miss mosaicism for several reasons. The variant may be present below the laboratory’s validated detection threshold. It may be absent or rare in blood but enriched in skin lesions, renal angiomyolipoma, brain tissue, saliva, buccal cells, or hair follicles. Standard sequencing filters may also remove low-frequency signals as technical noise.

Clues that justify mosaic-sensitive testing include:

  • convincing clinical TSC with negative standard sequencing and deletion analysis;
  • findings confined mainly to one side or body segment;
  • multiple TSC-associated lesions without a constitutional variant;
  • an apparently unaffected parent of a child with a “de novo” result who has subtle features;
  • differing variant fractions across specimens;
  • a variant detected at a low allele fraction on another test.

The next step may be high-depth sequencing of blood with a pipeline validated for low variant allele fractions. If negative, testing another accessible tissue can be considered. Skin biopsy should target a TSC-associated lesion when clinically appropriate rather than random normal skin. Archived tumor tissue can be informative, but a variant found only in a tumor may represent the second somatic hit rather than the constitutional or early mosaic predisposition. Comparing blood, normal tissue, and lesion tissue helps distinguish them.

A low variant fraction requires technical confirmation. Sequencing artifacts, clonal hematopoiesis, sample contamination, and tissue-specific somatic events can mimic constitutional mosaicism. Orthogonal methods such as droplet digital PCR may confirm and quantify a known variant.

Mosaicism changes counseling. An affected mosaic individual may have a child with the variant if germ cells are involved. The chance may be below 50%, but it cannot be calculated reliably from blood alone. A child who inherits the variant through an egg or sperm generally has it constitutionally and may be more extensively affected than the mosaic parent.

Gene-specific patterns and prognosis

TSC2 pathogenic variants are more common than TSC1 variants among diagnosed individuals. Across groups, TSC2 is associated with a higher average burden of several manifestations, including neurologic and renal disease. TSC1-associated disease is often milder on average. These are statistical tendencies, not dependable predictions for one person.

Severe TSC can occur with either gene. Members of the same family carrying the same variant can have very different seizure histories, cognitive profiles, kidney disease, skin findings, and tumor growth. A parent diagnosed only after a child’s severe presentation may have subtle features despite sharing the variant. This variable expression is central to counseling.

Some genotype findings do add specific context:

  • A large deletion involving TSC2 and PKD1 raises concern for early and potentially aggressive cystic kidney disease.
  • Certain TSC2 missense or splice variants may retain partial function, but individual outcome remains uncertain.
  • Mosaic variants may be associated with fewer manifestations on average, although widespread severe disease can occur.
  • The absence of a detectable variant does not imply a milder course.

The genetic report cannot predict whether an infant will develop spasms, whether a cortical tuber will be epileptogenic, whether a subependymal nodule will become a SEGA, whether an angiomyolipoma will bleed, or whether LAM will progress. Those risks require serial clinical measurements.

Prognosis is built from genotype plus current phenotype, age, lesion burden, EEG, developmental trajectory, kidney imaging and function, lung studies, and response to treatment. A molecular diagnosis is a starting signal for surveillance, not a complete forecast.

This distinction matters when testing a fetus or an asymptomatic relative. Finding the familial variant can determine that the person has TSC, but prenatal ultrasound or MRI cannot rule out later neurodevelopmental, seizure, renal, or skin manifestations. Counseling should separate certainty about diagnosis from uncertainty about severity.

Inheritance, recurrence risk, and family testing

TSC follows autosomal dominant inheritance. A person with a constitutional pathogenic TSC1 or TSC2 variant has a 50% chance of transmitting it in each pregnancy. The chance is the same for children of any sex, and each pregnancy is an independent event.

Approximately one third of diagnosed people have an affected parent, while about two thirds have an apparently de novo variant. “De novo” means the variant was not detected in the parents’ tested samples; it does not always mean recurrence risk is zero. A parent may have low-level somatic or gonadal mosaicism, and subtle clinical features can be overlooked.

After a child receives a diagnostic result, both biological parents should be offered targeted testing for the exact variant and a focused TSC examination. If a parent tests positive, their own surveillance is indicated and each of their children has a 50% chance. If both parents test negative in blood, recurrence risk for another pregnancy is low but remains above the general population because of possible gonadal mosaicism.

Siblings, children, and other at-risk relatives can receive predictive testing once the familial variant is known. Unlike carrier testing for a recessive condition, testing minors is medically relevant because a positive result changes childhood surveillance for seizures, brain lesions, kidney disease, cardiac findings, development, and other complications. Apparently unaffected relatives should not wait for symptoms when targeted testing is available.

A person with clinical TSC but no detected variant still has reproductive risk. If the diagnosis is constitutional, risk may approach the usual dominant 50%; if it is mosaic, risk may be lower but uncertain. Genetics professionals may use phenotype distribution, tissue testing, and reproductive history to refine the estimate.

Prenatal diagnosis by chorionic villus sampling or amniocentesis and preimplantation genetic testing for monogenic disease are possible when the familial variant is established. Fetal imaging can detect some findings, particularly cardiac rhabdomyomas and selected brain lesions, but normal imaging does not exclude TSC or predict a mild outcome. More information about the distinction between fetal screening and diagnosis appears in prenatal genetic testing.

What happens after a diagnostic result

A diagnostic TSC1 or TSC2 result should prompt coordinated baseline evaluation. The exact schedule should follow current consensus guidance and the person’s age and findings, but major domains include:

Brain and seizures. Brain MRI evaluates cortical tubers, subependymal nodules, and SEGA. Infants need close seizure education and EEG surveillance because epileptiform activity and infantile spasms can emerge before caregivers recognize typical seizures. Older children and adults require neurologic follow-up based on seizure history and lesion status.

TAND. Behavioral, intellectual, academic, psychiatric, neuropsychological, and psychosocial concerns should be screened regularly. TAND can affect people with normal intelligence and may change across development. A genetic diagnosis should open access to evaluation and support rather than imply a predetermined cognitive outcome.

Kidneys. Abdominal MRI assesses angiomyolipomas and cysts. Blood pressure and kidney function require ongoing monitoring. Sudden flank pain, blood in urine, dizziness, or signs of bleeding need urgent assessment. Kidney-preserving approaches are preferred when intervention is required.

Heart, lungs, skin, eyes, and teeth. Cardiac rhabdomyomas and rhythm problems are monitored according to age and symptoms. Adults at risk for LAM need symptom review and appropriate chest imaging and pulmonary testing. Skin, retinal, dental, and oral findings should be examined periodically.

mTOR inhibitors can treat selected growing SEGAs, renal angiomyolipomas, LAM, seizures, and skin manifestations, but treatment decisions depend on clinical criteria rather than genotype alone. Surgery, embolization, anti-seizure therapy, developmental services, and organ-specific care remain important.

A negative or VUS result does not justify stopping surveillance when clinical criteria are met. Conversely, a newly positive asymptomatic relative should receive baseline assessment before clinicians decide what ongoing schedule is appropriate. The practical value of germline genetic testing is that it connects molecular risk to prevention, early detection, and family care.

Keep one organized record containing the genetic report, variant classification, imaging summaries, EEG history, kidney measurements, medications, and family test results. Recontact the genetics team if the result was negative despite a strong phenotype, if mosaicism was not assessed, if a VUS remains unresolved, or if new testing methods become available. In TSC, a precise molecular result can improve care—but lifelong surveillance remains driven by the whole person, not just the variant.

References

Disclaimer

This article provides general education about TSC1 and TSC2 testing and does not replace care from a TSC specialty team, medical geneticist, neurologist, nephrologist, or other qualified clinician. A pathogenic result, a convincing clinical diagnosis with negative testing, suspected mosaicism, or an ongoing pregnancy requires individualized interpretation. Surveillance and treatment recommendations change with age, organ findings, and updated consensus guidance.

RELATED ARTICLESMORE FROM AUTHOR